Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation.

about

Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting

P2860

Q57483947-C3D4CCAE-0D60-4A48-8F82-6BFD531BE5BA

P2860

Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation.

Item

http://www.wikidata.org/entity/Q53837638

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Bioequivalence of HTX-019 (apr ...... two-way crossover evaluation.

@en

Bioequivalence of HTX-019 (apr ...... two-way crossover evaluation.

@nl

type

Item

label

Bioequivalence of HTX-019 (apr ...... two-way crossover evaluation.

@en

Bioequivalence of HTX-019 (apr ...... two-way crossover evaluation.

@nl

prefLabel

Bioequivalence of HTX-019 (apr ...... two-way crossover evaluation.

@en

Bioequivalence of HTX-019 (apr ...... two-way crossover evaluation.

@nl

P1476

Bioequivalence of HTX-019 (apr ...... two-way crossover evaluation.

@en

P2093

Barry Quart

http://www.w3.org/2001/XMLSchema#string

Mary Rose Keller

http://www.w3.org/2001/XMLSchema#string

Matt Cravets

http://www.w3.org/2001/XMLSchema#string

Neil Clendeninn

http://www.w3.org/2001/XMLSchema#string

Tom Ottoboni

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting

Highly frequent and enhanced injection site reaction induced by peripheral venous injection of fosaprepitant in anthracycline-treated patients

Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.

Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2388 health care providers

An analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy.

Aprepitant and fosaprepitant: a 10-year review of efficacy and safety

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.

Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial

Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy.

Efficacy and Safety of Neurokinin-1 Receptor Antagonists for Prevention of Chemotherapy-Induced Nausea and Vomiting: Systematic Review and Meta-analysis of Randomized Controlled Trials.

P304

429-435

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/DDDT.S155875

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29535504

http://www.w3.org/2001/XMLSchema#string

P932

5837372

http://www.w3.org/2001/XMLSchema#string

Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation.

about

P2860

P2860

Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932